Transcripta Bio
Transcripta Bio is a Palo Alto-based biotech using a proprietary Drug-Gene Atlas and Conductor AI to discover and repurpose drugs at transcriptome scale, partnering with biopharma companies, research centers, and patient foundations targeting genetically validated diseases.
- Company typePrivate
- Founded2023
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Transcripta Bio does
Transcripta Bio is a privately held, Palo Alto-based biotechnology company building a transcriptome-first drug discovery platform. Its core offering combines a proprietary high-throughput RNA-Seq screening lab (the Discovery Platform), a large proprietary database mapping molecular structure and drug action to whole-cell transcriptomes (the Drug-Gene Atlas, built from over 200 million lab experiments in two years), and a proprietary AI modeling suite called Conductor AI that predicts gene expression directly from the molecular structure of uncharacterized compounds and virtually screens billions of candidates. The platform operates as a closed-loop system: wet-lab results feed the AI, AI predictions are validated in the lab, and the cycle repeats to advance multiple drug programs in parallel. The company focuses on indications where human genetics unequivocally establishes disease causality, and it has reported moving five FDA-approved drugs into single-patient studies for new indications in under two years — a process it characterizes as compressing timelines that would normally take five to eight years.
Transcripta Bio generates revenue through drug discovery partnerships with biopharma companies (structured as licensing and royalty arrangements), supplemented by data monetization via its CRISPR interference dataset distributed through Verily's (Alphabet) Pre precision health platform. Customer segments are primarily biopharma enterprise partners and patient foundations, with academic and clinical researchers reached indirectly via the Verily channel. The company is founder-led (CEO/CSO Chris Moxham, PhD, with Elizabeth Iorns as Scientific Founder & Advisor), venture-backed by JAZZ Venture Partners and BlueYard Capital plus family offices, recognized on the TIME100 Most Influential Companies 2024 list, and headquartered in Palo Alto, California with 11-50 employees.
Transcripta Bio firmographics
Firmographics- Name
- Transcripta Bio
- Legal name
- Transcripta Bio, Inc.
- Website
- https://transcriptabio.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Transcripta Bio is a Palo Alto-based biotech using a proprietary Drug-Gene Atlas and Conductor AI to discover and repurpose drugs at transcriptome scale, partnering with biopharma companies, research centers, and patient foundations targeting genetically validated diseases.
- Ownership category
- akta.pro rank
Transcripta Bio industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industry
- Transcriptomics & Gene Expression Profiling Services (HLAGANAE)
Keywords
Where Transcripta Bio is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Transcripta Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Drug Discovery Partnerships: Transcripta Bio enters into partnerships with biopharma companies to discover and develop new therapies. The company leverages its platform to identify therapeutic candidates that rebalance gene expression, advancing drug candidates through development in collaboration with partners.
- Data Licensing: Transcripta provides CRISPR interference datasets through Verily's Pre platform, enabling researchers to access transcriptomic data for drug discovery research purposes.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Transcripta Bio product offering
Product offeringCore offering
Transcripta Bio operates an integrated AI-powered drug discovery platform that combines high-throughput RNA-Seq wet-lab screening with a proprietary AI modeling suite (Conductor AI) trained on a proprietary transcriptome database (Drug-Gene Atlas). The platform maps molecular structure to whole-cell gene expression to identify therapeutic candidates that rebalance gene expression, with focus on diseases where genetic causality is established.
Product overview
Transcripta Bio is a platform drug development biotechnology company offering an integrated drug discovery ecosystem consisting of the Drug-Gene Atlas (a proprietary transcriptome database), the Discovery Platform (high-throughput RNA-Seq screening), and Conductor AI (predictive modeling suite). These three components work together in a closed-loop system: wet lab results from the Discovery Platform feed into Conductor AI, which virtually screens billions of compounds to predict therapeutic candidates, with findings validated back in the lab. The platform focuses on diseases where causality is established by human genetics, using small molecules to rebalance gene expression.
Differentiator
Problem solved
Functional benefit
Brands
- Conductor AI: Proprietary AI modeling suite that predicts gene expression directly from molecular structure of compounds, trained on Transcripta's Drug-Gene Atlas dataset.
- Drug-Gene Atlas
Quantifiable outcome
- Reduced drug discovery timelines from years/months to months/weeks
- +3 more outcomes
Companies that use Transcripta Bio
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Transcripta Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Transcripta Bio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Verily (Alphabet)coreTranscripta Bio provides CRISPR interference dataset mapping gene knockdowns linked to rare diseases as part of Verily's Pre precision health platform. This integration enables researchers to access Transcripta's transcriptomic data through Verily's self-serve platform.
- Leading Biopharma CompaniescoreTranscripta Bio is partnering with leading biopharma companies to uncover and advance new drug discovery opportunities, leveraging the company's transcriptome-based AI platform and Drug-Gene Atlas database.
- Research CentersmajorTranscripta Bio partners with research centers to advance drug discovery using their high-throughput screening platform and AI capabilities.
- Patient FoundationsmajorTranscripta Bio partners with patient foundations to uncover and advance new therapeutic opportunities, with particular focus on rare diseases where genetic causality is established.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Transcripta Bio competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning. Recursion operates a similar 'closed-loop' model and is a leading direct competitor in the AI-enabled small molecule discovery space.
- Insitro: Machine learning-driven drug discovery platform using high-throughput biology and proprietary data generation. Insitro is a direct competitor pursuing AI-enabled small molecule discovery with biopharma partnerships.
- Schrödinger, Inc. Computational chemistry and molecular simulation platform used for drug discovery across biopharma. Schrödinger is a direct competitor offering AI/ML-driven virtual screening and small molecule design tools.
- Exscientia: AI-driven drug design company using precision medicine and active learning for small molecule discovery. Exscientia competes directly with Transcripta Bio in AI-enabled biopharma partnerships and pipeline development.
- XtalPi: AI + robotics drug discovery platform combining quantum physics, cloud computing, and high-throughput experimentation. XtalPi is a direct peer using AI/ML + wet-lab integration for small molecule discovery.
- Verge Genomics: AI-driven drug discovery company using human omics data (including transcriptomics) to identify therapeutic targets. Verge's omics-first approach closely mirrors Transcripta's transcriptome-centric strategy.
- Lantern Pharma: AI-driven oncology drug discovery and repurposing company using machine learning and genomic data to identify responders. Lantern's drug repurposing focus on approved pharmaceuticals overlaps with Transcripta's indication-expansion approach.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company leveraging DeepMind's protein structure prediction and broader computational biology capabilities. Isomorphic Labs is an Alphabet-incumbent competitor with substantially greater resources.
Emerging players
- BPGbio: AI-powered biopharma using multi-omics data (including transcriptomics) and proprietary biological models for drug discovery. BPGbio represents a comparable AI + omics platform emerging player.
- Owkin: AI biology platform leveraging multi-modal patient data for target discovery and drug development. Owkin shares Transcripta's AI + biology thesis but focuses more on federated learning and clinical data than wet-lab perturbation screens.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Transcripta Bio social profiles
Digital presenceTranscripta Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Transcripta Bio leadership team
Management profileNumber of profiles
Profiles2 records
Transcripta Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Transcripta Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Transcripta Bio
What does Transcripta Bio do?
Transcripta Bio operates an integrated AI-powered drug discovery platform that combines high-throughput RNA-Seq wet-lab screening with a proprietary AI modeling suite (Conductor AI) trained on a proprietary transcriptome database (Drug-Gene Atlas). The platform maps molecular structure to whole-cell gene expression to identify therapeutic candidates that rebalance gene expression, with focus on diseases where genetic causality is established.
Is Transcripta Bio a public or private company?
Transcripta Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Transcripta Bio founded?
Transcripta Bio was founded in 2023. It employs 11 to 50 people.
Where is Transcripta Bio based?
Transcripta Bio is headquartered in Palo Alto, United States, in the North America region.
How does Transcripta Bio make money?
Two revenue lines are on record. Drug Discovery Partnerships are the primary driver. The others are data Licensing.
Who are Transcripta Bio's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Schrödinger, Inc., Exscientia, XtalPi, Verge Genomics and Lantern Pharma. Isomorphic Labs is listed as a broad incumbent. Emerging players are BPGbio and Owkin.
Does Transcripta Bio have an API?
No public API is recorded for Transcripta Bio.
What industry is Transcripta Bio in?
Transcripta Bio's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714.